Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.42 |
| ▸ | EML4 | Q9HC35 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20548788 | 0.90 | EGFR (0.45) | EGFRALKEML4 | |
| SCHEMBL35210280 | 0.89 | EGFR (0.61) | EGFRALKEML4 | |
| SCHEMBL20548739 | 0.89 | EGFR (0.61) | EGFRALKEML4 | |
| SCHEMBL20548849 | 0.87 | EGFR (0.53) | EGFRALKEML4 | |
| SCHEMBL20548909 | 0.86 | EGFR (0.47) | EGFRALKEML4 | |
| SCHEMBL20548863 | 0.84 | EGFR (0.46) | EGFRALKEML4 | |
| SCHEMBL20548845 | 0.84 | EGFR (0.46) | EGFRALKEML4 | |
| SCHEMBL20548969 | 0.84 | EGFR (0.54) | EGFRALKEML4 | |
| SCHEMBL20548764 | 0.82 | EGFR (0.61) | EGFRALKEML4 | |
| SCHEMBL35210263 | 0.82 | EGFR (0.61) | EGFRALKEML4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3398939-B1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2026-05-06 | — | — | EP | claimed |
| EP-3398939-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | Ancureall Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2018-11-07 | — | — | EP | claimed |
| EP-3398939-B1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-07-09 | — | — | US | disclosed |
| EP-3398939-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | Ancureall Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2018-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | EGFR, ABL1, CSNK1A1 | EGFR 1/4885ALK 54/4885EML4 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.